Early research (Phase 1)Ended earlyNCT03432741
What this trial is testing
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Who this might be right for
Breast AdenocarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma+11 more
Mayo Clinic 17